Actively Recruiting
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Led by Susan Bal · Updated on 2026-02-13
25
Participants Needed
1
Research Sites
824 weeks
Total Duration
On this page
Sponsors
S
Susan Bal
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
CONDITIONS
Official Title
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years with no upper age limit
- Newly diagnosed multiple myeloma with therapy needed and diagnosis within the last 12 months
- Not eligible for or deferring autologous stem cell transplant based on institutional criteria or personal choice
- ECOG performance status of 0 to 1
- Adequate organ function
You will not qualify if you...
- Active or past central nervous system involvement of multiple myeloma
- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or significant amyloidosis
- History of other cancers
- Uncontrolled infection
- Other protocol-defined exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
Research Team
S
Susan Bal, MD
CONTACT
M
Margaret Thomas, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here